AstraZeneca (GB:AZN) has released an update.
AstraZeneca’s Imfinzi, combined with chemotherapy, has shown a significant improvement in survival rates for muscle-invasive bladder cancer patients in its NIAGARA Phase III trial. The treatment regimen, which includes pre- and post-surgery immunotherapy, aims to transform the standard of care and reduce disease recurrence. Imfinzi’s safety profile was consistent with expectations, and the results will be used to seek global regulatory approvals.
For further insights into GB:AZN stock, check out TipRanks’ Stock Analysis page.
